• Completed

NCT04436029: Phase 2: Descartes-11 Consolidation Treatment Patients With High-Risk Multiple Myeloma

Updated: May 23

NCT04436029: Phase 2: Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy


descartes11

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy


To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.


Sponsor

Cartesian Therapeutics


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT04436029


Official Title: Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy


First Posted : June 17, 2020


Click here to see details on ClinicalTrials.gov

 

Biological: Descartes 11 Car T-cells

 

Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11


Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11 (Code C173434)

Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11

Autologous CD8+ T-cells Expressing Anti-BCMA CAR Descartes-11

Descartes 11

Descartes-011

Descartes-11

Descartes11

 

Locations

United States, Maryland

United States, New Jersey

United States, Oklahoma

United States, Wisconsin





Posts Archive